BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/13/2025 1:39:50 PM | Browse: 91 | Download: 552
 |
Received |
|
2025-03-27 02:28 |
|
Peer-Review Started |
|
2025-03-27 02:28 |
|
First Decision by Editorial Office Director |
|
2025-04-03 08:52 |
|
Return for Revision |
|
2025-04-03 08:52 |
|
Revised |
|
2025-04-16 15:21 |
|
Publication Fee Transferred |
|
2025-04-17 09:35 |
|
Second Decision by Editor |
|
2025-05-21 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-05-21 08:08 |
|
Articles in Press |
|
2025-05-21 08:08 |
|
Edit the Manuscript by Language Editor |
|
2025-05-23 11:03 |
|
Typeset the Manuscript |
|
2025-06-04 05:17 |
|
Publish the Manuscript Online |
|
2025-06-13 13:39 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medical Ethics |
| Manuscript Type |
Case Report |
| Article Title |
Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiang-Lei Kong, Xi-Wei Lu, Si-Qi Dong, Jiao Liu, Lei Zheng, Lan-Lan Chen, Zi-Hui An, Li-Ming Gao and Jun-Li Cao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Science Research Project of Hebei Province in 2023, Key Laboratory of Research on Molecular Mechanism of Gastrointestinal Tumors in Qinhuangdao |
20231891 |
|
| Corresponding Author |
Jun-Li Cao, Department of Oncology, The First Hospital of Qinhuangdao, The Affiliated Qinhuangdao First Hospital of Hebei Medical University, No. 258 Wenhua Road, Qinhuangdao 066000, Hebei Province, China. kongxianglei@qhdsdyyy.com |
| Key Words |
Duodenal malignancy; Microsatellite instability-high; High expression of programmed cell death-ligand 1; Pembrolizumab; Complete clinical response; Case report |
| Core Tip |
Descending duodenal adenocarcinoma (DDA) is a rare malignancy of the digestive system. We treated a patient with DDA characterized by microsatellite instability-high (MSI-H) and high programmed cell death-ligand 1 expression, customizing the treatment regimen for individualized pembrolizumab therapy based on our clinical experience and disease assessment. The patient achieved long-term clinical remission with satisfactory results. This case underscores the advantages of individualized therapy and confirms that patients with mismatch-repair deficiency/MSI-H can derive significant benefits from pembrolizumab. |
| Publish Date |
2025-06-13 13:39 |
| Citation |
Kong XL, Lu XW, Dong SQ, Liu J, Zheng L, Chen LL, An ZH, Gao LM, Cao JL. Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and review of literature. World J Gastrointest Oncol 2025; 17(6): 107568 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i6/107568.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i6.107568 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
